Radiofrequency ablation versus endoscopic submucosal dissection in treating large early esophageal squamous cell Neoplasia

Wen Lun Wang, I. Wei Chang, Chien Chuan Chen, Chi Yang Chang, Lein Ray Mo, Jaw Town Lin, Hsiu Po Wang, Ching Tai Lee

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Radiofrequency ablation (RFA) and endoscopic submucosal dissection (ESD) can potentially be applied for early esophageal squamous cell neoplasia (ESCN); however, no study has directly compared these 2 modalities. We retrospectively enrolled the patients with flat-type large (length ≥3 cm extending ≥1/2 of the circumference of esophagus) early ESCNs treated endoscopically. The main outcome measurements were complete response at 12 months, and adverse events. Of a total of 65 patients, 18 were treated with RFA and 47 with ESD. The procedure time of RFA was significantly shorter than that of ESD (126.6 vs 34.8 min; P<0.001). The complete resection rate of ESD and complete response rate after primary RFA were 89.3% and 77.8%, respectively. Based on the histological evaluation of the post-ESD specimens showed 14 of 47 (29.8%) had histological upstaging compared with the pre-ESD biopsies, and 4 of them had lymphovascular invasion requiring chemoradiation or surgery. After additional therapy for residual lesions, 46 (97.9%) patients in the ESD group and 17 (94.4%) patients in the RFA group achieved a complete response at 12 months. Four patients (8.5%) developed major procedure-related adverse events in the ESD group, but none in the RFAgroup. In patientswith lesions occupyingmore than 3/4 of the circumference, a significantly higher risk of esophageal stenosis was noted in the ESD group compared with RFA group (83% vs 27%, P=0.01), which required more sessions of dilatation to resolve the symptoms (median, 13 vs 3, P=0.04). There were no procedure-related mortality or neoplastic progression in either group; however, 1 patient who received ESD and 1 who received RFA developed local recurrence during a median follow-up period of 32.4 (range, 13-68) and 18.0 (range, 13-41) months, respectively. RFA and ESD are equally effective in the short-term treatment of early flat large ESCNs; however, more adverse events occur with ESD, especially in lesions extending more than 3/4 of the circumference. RFA does not allow for pathology to evaluate the curability after ablation, and thus currently the use for invasive ESCNs should be conservative until longer follow-up studies are available.

Original languageEnglish
Article numbere2240
JournalMedicine (United States)
Volume94
Issue number49
DOIs
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Epithelial Cells
Neoplasms
Endoscopic Mucosal Resection
Esophageal Stenosis
Esophagus
Dilatation
Pathology
Biopsy
Recurrence
Mortality
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Radiofrequency ablation versus endoscopic submucosal dissection in treating large early esophageal squamous cell Neoplasia. / Wang, Wen Lun; Chang, I. Wei; Chen, Chien Chuan; Chang, Chi Yang; Mo, Lein Ray; Lin, Jaw Town; Wang, Hsiu Po; Lee, Ching Tai.

In: Medicine (United States), Vol. 94, No. 49, e2240, 01.01.2015.

Research output: Contribution to journalArticle

Wang, Wen Lun ; Chang, I. Wei ; Chen, Chien Chuan ; Chang, Chi Yang ; Mo, Lein Ray ; Lin, Jaw Town ; Wang, Hsiu Po ; Lee, Ching Tai. / Radiofrequency ablation versus endoscopic submucosal dissection in treating large early esophageal squamous cell Neoplasia. In: Medicine (United States). 2015 ; Vol. 94, No. 49.
@article{a3b277ca2fbd41f48f88abcf34fa5db2,
title = "Radiofrequency ablation versus endoscopic submucosal dissection in treating large early esophageal squamous cell Neoplasia",
abstract = "Radiofrequency ablation (RFA) and endoscopic submucosal dissection (ESD) can potentially be applied for early esophageal squamous cell neoplasia (ESCN); however, no study has directly compared these 2 modalities. We retrospectively enrolled the patients with flat-type large (length ≥3 cm extending ≥1/2 of the circumference of esophagus) early ESCNs treated endoscopically. The main outcome measurements were complete response at 12 months, and adverse events. Of a total of 65 patients, 18 were treated with RFA and 47 with ESD. The procedure time of RFA was significantly shorter than that of ESD (126.6 vs 34.8 min; P<0.001). The complete resection rate of ESD and complete response rate after primary RFA were 89.3{\%} and 77.8{\%}, respectively. Based on the histological evaluation of the post-ESD specimens showed 14 of 47 (29.8{\%}) had histological upstaging compared with the pre-ESD biopsies, and 4 of them had lymphovascular invasion requiring chemoradiation or surgery. After additional therapy for residual lesions, 46 (97.9{\%}) patients in the ESD group and 17 (94.4{\%}) patients in the RFA group achieved a complete response at 12 months. Four patients (8.5{\%}) developed major procedure-related adverse events in the ESD group, but none in the RFAgroup. In patientswith lesions occupyingmore than 3/4 of the circumference, a significantly higher risk of esophageal stenosis was noted in the ESD group compared with RFA group (83{\%} vs 27{\%}, P=0.01), which required more sessions of dilatation to resolve the symptoms (median, 13 vs 3, P=0.04). There were no procedure-related mortality or neoplastic progression in either group; however, 1 patient who received ESD and 1 who received RFA developed local recurrence during a median follow-up period of 32.4 (range, 13-68) and 18.0 (range, 13-41) months, respectively. RFA and ESD are equally effective in the short-term treatment of early flat large ESCNs; however, more adverse events occur with ESD, especially in lesions extending more than 3/4 of the circumference. RFA does not allow for pathology to evaluate the curability after ablation, and thus currently the use for invasive ESCNs should be conservative until longer follow-up studies are available.",
author = "Wang, {Wen Lun} and Chang, {I. Wei} and Chen, {Chien Chuan} and Chang, {Chi Yang} and Mo, {Lein Ray} and Lin, {Jaw Town} and Wang, {Hsiu Po} and Lee, {Ching Tai}",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/MD.0000000000002240",
language = "English",
volume = "94",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "49",

}

TY - JOUR

T1 - Radiofrequency ablation versus endoscopic submucosal dissection in treating large early esophageal squamous cell Neoplasia

AU - Wang, Wen Lun

AU - Chang, I. Wei

AU - Chen, Chien Chuan

AU - Chang, Chi Yang

AU - Mo, Lein Ray

AU - Lin, Jaw Town

AU - Wang, Hsiu Po

AU - Lee, Ching Tai

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Radiofrequency ablation (RFA) and endoscopic submucosal dissection (ESD) can potentially be applied for early esophageal squamous cell neoplasia (ESCN); however, no study has directly compared these 2 modalities. We retrospectively enrolled the patients with flat-type large (length ≥3 cm extending ≥1/2 of the circumference of esophagus) early ESCNs treated endoscopically. The main outcome measurements were complete response at 12 months, and adverse events. Of a total of 65 patients, 18 were treated with RFA and 47 with ESD. The procedure time of RFA was significantly shorter than that of ESD (126.6 vs 34.8 min; P<0.001). The complete resection rate of ESD and complete response rate after primary RFA were 89.3% and 77.8%, respectively. Based on the histological evaluation of the post-ESD specimens showed 14 of 47 (29.8%) had histological upstaging compared with the pre-ESD biopsies, and 4 of them had lymphovascular invasion requiring chemoradiation or surgery. After additional therapy for residual lesions, 46 (97.9%) patients in the ESD group and 17 (94.4%) patients in the RFA group achieved a complete response at 12 months. Four patients (8.5%) developed major procedure-related adverse events in the ESD group, but none in the RFAgroup. In patientswith lesions occupyingmore than 3/4 of the circumference, a significantly higher risk of esophageal stenosis was noted in the ESD group compared with RFA group (83% vs 27%, P=0.01), which required more sessions of dilatation to resolve the symptoms (median, 13 vs 3, P=0.04). There were no procedure-related mortality or neoplastic progression in either group; however, 1 patient who received ESD and 1 who received RFA developed local recurrence during a median follow-up period of 32.4 (range, 13-68) and 18.0 (range, 13-41) months, respectively. RFA and ESD are equally effective in the short-term treatment of early flat large ESCNs; however, more adverse events occur with ESD, especially in lesions extending more than 3/4 of the circumference. RFA does not allow for pathology to evaluate the curability after ablation, and thus currently the use for invasive ESCNs should be conservative until longer follow-up studies are available.

AB - Radiofrequency ablation (RFA) and endoscopic submucosal dissection (ESD) can potentially be applied for early esophageal squamous cell neoplasia (ESCN); however, no study has directly compared these 2 modalities. We retrospectively enrolled the patients with flat-type large (length ≥3 cm extending ≥1/2 of the circumference of esophagus) early ESCNs treated endoscopically. The main outcome measurements were complete response at 12 months, and adverse events. Of a total of 65 patients, 18 were treated with RFA and 47 with ESD. The procedure time of RFA was significantly shorter than that of ESD (126.6 vs 34.8 min; P<0.001). The complete resection rate of ESD and complete response rate after primary RFA were 89.3% and 77.8%, respectively. Based on the histological evaluation of the post-ESD specimens showed 14 of 47 (29.8%) had histological upstaging compared with the pre-ESD biopsies, and 4 of them had lymphovascular invasion requiring chemoradiation or surgery. After additional therapy for residual lesions, 46 (97.9%) patients in the ESD group and 17 (94.4%) patients in the RFA group achieved a complete response at 12 months. Four patients (8.5%) developed major procedure-related adverse events in the ESD group, but none in the RFAgroup. In patientswith lesions occupyingmore than 3/4 of the circumference, a significantly higher risk of esophageal stenosis was noted in the ESD group compared with RFA group (83% vs 27%, P=0.01), which required more sessions of dilatation to resolve the symptoms (median, 13 vs 3, P=0.04). There were no procedure-related mortality or neoplastic progression in either group; however, 1 patient who received ESD and 1 who received RFA developed local recurrence during a median follow-up period of 32.4 (range, 13-68) and 18.0 (range, 13-41) months, respectively. RFA and ESD are equally effective in the short-term treatment of early flat large ESCNs; however, more adverse events occur with ESD, especially in lesions extending more than 3/4 of the circumference. RFA does not allow for pathology to evaluate the curability after ablation, and thus currently the use for invasive ESCNs should be conservative until longer follow-up studies are available.

UR - http://www.scopus.com/inward/record.url?scp=84952656034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952656034&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000002240

DO - 10.1097/MD.0000000000002240

M3 - Article

C2 - 26656367

AN - SCOPUS:84952656034

VL - 94

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 49

M1 - e2240

ER -